Heritability and the Genetic Correlation of Heart Rate Variability and Blood Pressure in &gt;29 000 Families The Lifelines Cohort Study:The Lifelines Cohort Study by Tegegne, Balewgizie S et al.
 
 
 University of Groningen
Heritability and the Genetic Correlation of Heart Rate Variability and Blood Pressure in >29
000 Families The Lifelines Cohort Study
Tegegne, Balewgizie S; Man, Tengfei; van Roon, Arie M; Asefa, Nigus G; Riese, Harriëtte;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Tegegne, B. S., Man, T., van Roon, A. M., Asefa, N. G., Riese, H., Nolte, I., & Snieder, H. (2020).
Heritability and the Genetic Correlation of Heart Rate Variability and Blood Pressure in >29 000 Families
The Lifelines Cohort Study: The Lifelines Cohort Study. Hypertension, 76(4), 1256-1262.
https://doi.org/10.1161/HYPERTENSIONAHA.120.15227
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
1256
Heart rate variability (HRV), reflecting beat-to-beat fluctua-tions in heart rate over time,1 has emerged as one of the most 
widely used noninvasive indices of cardiac autonomic nervous 
system function. The imbalance of the autonomic cardiovascular 
control plays a key role in the risk for high blood pressure (BP).2 
The modulation of vagal tone helps to maintain the dynamic au-
tonomic function necessary for short-term BP regulation. More 
specifically, sympathetic inhibition reduces peripheral resist-
ance, while parasympathetic activation attenuates heart rate and 
contractility. Conversely, sympathetic activation and subsequent 
parasympathetic inactivation allow the baroreflex to elevate BP.3 
Both cross-sectional4 and prospective5,6 studies have shown asso-
ciations between low HRV and high BP, suggesting an essential 
role of lower HRV in the development of hypertension.
Besides the established demographic7 and lifestyle factors8 
that have been reported to explain the individual differences 
in HRV level at rest, numerous studies have shown that ge-
netic factors contribute substantially to the variance. For ex-
ample, Sinnreich et al9 reported heritability estimates of 41% 
and 39% for SD of normal-to-normal intervals (SDNN) and 
root mean square of successive differences (RMSSD), respec-
tively, based on 5-minute Holter recordings in the Kibbutzim 
family study. Recent investigations from the Oman Family 
Study10,11 reported heritability estimates of 12.3% to 20.5% 
from 10-minute ECG recordings in a supine position. In twin 
studies, the genetic contribution to individual differences in 
HRV measures can be as high as 74%.12,13 Likewise, previous 
studies reported that individual differences in BP traits, such 
as systolic BP (SBP), diastolic BP (DBP), and pulse pressure 
(PP), could for a large part be accounted for by genetic fac-
tors.14 In a meta-analysis of published twin studies, Wang et 
al15 reported that the pooled heritabilities of SBP, DBP, and PP 
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were 54%, 49%, and 50%, respectively. Family-based studies 
from Switzerland,16 Oman,10,17 and the Seychelles18 reported 
heritability estimates ranging from 19% to 24% for SBP, 5% 
to 25% for DBP, and 18% to 37% for PP.
Although the studies mentioned above have shown the 
contribution of genetic factors for individual variation in HRV 
and BP, heritability estimates were from relatively small sam-
ples. Moreover, most of these studies did not correctly adjust 
for the well-known and recently more recognized effect of 
heart rate on HRV.19 Thus, large population-based family stud-
ies are needed for better understanding of the genetic effects.
Additionally, although an association between HRV and 
hypertension was found in many epidemiological studies, the 
underlying pathophysiological mechanisms are not yet fully 
understood. Given that HRV and BP are both heritable, we 
hypothesized that shared genetic factors may partly explain 
the negative association between the 2 traits. In this study, we 
aimed to (1) determine the genetic contributions to individual 
differences in both HRV and BP and (2) estimate the magni-
tude of any potential genetic overlap between HRV and BP. We 
used data from the population-based Lifelines Cohort Study 
and Biobank,20 which with its 3-generation family design, large 
sample size, and broad age range is ideally suited for this study.
Methods
Data Availability
The data that were used in this study are available from the Lifelines 
Cohort Study and Biobank (research@lifelines.nl) upon reasonable 
request. Lifelines is a facility that is open for all researchers; informa-
tion on application and data access procedures is available on https://
www.lifelines.nl/researcher/how-to-apply.
Study Setting and Population
The Lifelines Cohort Study and Biobank with >167 000 participants is 
a large population-based prospective study in the northern part of the 
Netherlands, aiming to investigate risk factors for multifactorial dis-
eases. The design and cohort profile of the Lifelines study have been 
described before.20,21 In short, baseline data were collected between 
2006 and 2013. The recruitment of the Lifelines study was family based 
by design. Eligible participants between 20 and 50 years of age were 
invited to participate through their general practitioners. After the inclu-
sion of these individuals, their partner, children, parents, and partner’s 
parents were also invited to participate in the study. In addition, single 
individuals could register for participation online. In this way, a 3-gen-
eration family study was realized. Subsequently, we used the informa-
tion on family members and information on (anonymized) names and 
birth dates of parents provided by all participants in questionnaires to 
define relationships between undefined family members in Lifelines. 
For instance, 2 sibs could participate in Lifelines and obtained different 
family IDs, if they were invited by their respective spouses. This pro-
cess resulted in 40 496 singletons (ie, individuals without any relative 
in the sample) and 30 914 families (of size ≥2) of up to 4 generations 
with an average family size of 4.12. The largest family connected 189 
participants. Spouses without children were considered as a family of 
size 2, even though they are genetically unrelated. The Figure shows an 
example of 23-member Lifelines family extending over 4 generations.
During the baseline visit, ECG recordings were obtained from 
153 793 participants (91.8%) aged ≥13 years. From these, HRV could 
not be calculated in 4586 participants due to excessive noise and ec-
topic (nonsinus node) beats and 140 were excluded due to extreme 
values (<5 or >5 SD from the mean) for either HRV or BP meas-
ures. In the current analysis, 149 067 individuals (1.03% children; 
96.5% European ancestry) with an age range of 13 to 94 years were 
included, of whom 40 955 were singletons. The remaining individuals 
belonged to a total of 29 107 families with an average family size of 
3.71. The largest family connected 169 participants.
All participants signed an informed consent. The Lifelines co-
hort study is conducted according to the principles of the declaration 
of Helsinki and following the research code of University Medical 
Center Groningen and approved by its Medical Ethical Committee.
Measurements
A 10-second 12-lead resting ECG was recorded while partici-
pants were in a supine resting position. For the ECG recording, 
CardioPerfect software (Welch Allyn DT100 recorder; Welch Allyn, 





) were selected to detect R peaks in the ECG. The details of HRV 
calculation in Lifelines have been published previously.7 In short, 
ECG recordings were excluded from HRV calculation if (1) the 
number of beats were <5, (2) the ratio between maximal and minimal 
interbeat interval (IBI) exceeded 1.4 indicating a missing trigger or 
extrasystolic beat, (3) there was extremely low variability (defined as 
the SD of IBI <1.2 ms), or (4) <60% of the recording time was in-
cluded in the calculation. In-house software was used to calculate the 
RMSSD and SDNN as indices of HRV, which are used in the present 
study. Heart rate has a well-established strong inverse relationship 
with HRV, which includes a mathematical dependency of the variance 
in IBI on the mean IBI that is unrelated to the underlying biology. Our 
group has reintroduced a recommended approach to correct HRV for 
its dependency on the mean IBI of consecutive R peaks using coeffi-
cients of variation.19,22 The coefficient of variation detects the amount 
of IBI variability relative to the mean IBI of each participant. We 
applied this method to additionally calculate HRV values that were 
corrected for the influence of mean IBI. Heart rate was calculated 
from the ECG recording using 60 000/(mean IBI).
Simultaneously with the ECG recordings, BP was measured with an 
automatic BP monitor (DinaMap, PRO 100V2) every minute during 10 
minutes while the participant was in a supine resting position. The mean 
of the last 3 measures was used to calculate SBP and DBP. For par-
ticipants taking antihypertensive medication (see below), we corrected 
the measured BP values by adding 15 mm Hg for SBP and 10 mm Hg 
for DBP.23 From the adjusted BP values, PP and mean arterial pressure 
(MAP) were calculated as PP=SBP−DBP and MAP=(2 DBP+SBP)/3.
Medications and diseases that have been reported to influence 
HRV were included as covariates. Participants self-reported prescrip-
tion during the baseline visit, which were classified according to the 
Anatomical Therapeutic Chemical classification, were used to define 
medications. A list of Anatomical Therapeutic Chemical codes pre-
scribed to treat hypertension, depression, type 2 diabetes mellitus, 
and cardiovascular diseases in the Netherlands was retrieved from the 
Dutch Pharmacotherapeutic Compass (https://www.farmacotherapeu-
tischkompas.nl). Participants were considered to have cardiovascular 
disease if they self-reported one of the following diseases: (1) heart 
failure, atrial fibrillation, and vascular diseases (myocardial infarction, 
stroke, and aneurysm) and (2) if participants used medications related 
to these symptoms (β-blockers, angiotensin-converting enzyme inhib-
itors, diuretics, vitamin K antagonist, statins, aspirin, and clopidogrel). 
Any participant who had either self-reported type 2 diabetes melli-
tus, use of antidiabetes medication(s), a fasting blood glucose ≥7.0 
mmol/L, or HbA1c ≥6.5% was considered to have type 2 diabetes 
mellitus. Hypertension was defined as having SBP ≥140 mm Hg or 
DBP ≥90 mm Hg or use of antihypertensive medication. Body mass 
index was calculated as weight/height squared and expressed in kg/m2.
Statistical Analysis
The baseline characteristics of participants, stratified by sex, were 
described as mean and SD for continuous traits and as percentages for 
categorical variables. A natural logarithmic transformation was com-
puted to achieve approximate normality of HRV indices. ANOVA and 
χ2 tests were used to compare any differences between men and women.
Heritability Estimate
Heritability is defined as the proportion of phenotypic variation 
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For the univariate analyses, we assumed a linear mixed model for the 
heritability analysis as follows: y Xb Z a Z f e,a f= + + +  where y is a 
vector of the response variable (HRV or BP); b, vector of regression 
coefficients for the fixed effects; a, additive genetic effects with vari-
ance σ2
a
A; f, family (shared environment) effects with variance σ2
f
I; 
and e, residuals (environmental effects) with variance σ2
e
I. X is the 
design matrix of the fixed effects, Z
a
 is the design matrix mapping 
subjects to the genetic kinship (relationship) matrix A, and Z
f
 is the 
design matrix for family (group) effects. There are no known genetic 
relationships between individuals in different families.
Once the total and phenotypic variances were estimated from 
the linear mixed model, narrow-sense heritability was calculated as 
h a a f e
2 2 2 2 2= + +( )σ σ σ σ/ ,  where σ2a is the additive genetic variance, 
σ2
f
 is the shared environmental variance, and σ2
e
 is the residual (en-
vironmental) variance. The singletons were included in the analysis 
and contributed to the estimations of variances and phenotypic cor-
relations but not to the genetic correlations.
Genetic Correlation Estimate
The genetic correlations were estimated using the same designs and 
similar methods as used to estimate heritability in an expanded set 
of equations (ie, a bivariate model). In the bivariate analyses, the 
genetic correlations between HRV and BP were obtained from the 









,  where σAxAy is the additive genetic covariance be-




 is the additive genetic vari-
ance for traits x and y, respectively.
To test the significance of the h2 estimates (h2>0) and genetic 
correlations (|r
G
|>0), the model in which all variances and correla-
tions were estimated was compared, using a likelihood-ratio test, to 
a model in which additive genetic variances and genetic correlations 
for all measures were constrained to be zero. Similarly, genetic cor-
relations were constrained to be equal to 1 or −1 to test the presence 
of complete overlap of genetic effects (|r
G
|=1).24 In all analyses, the 
fixed effects (or covariates) included age, sex, and body mass index. 
Age squared was also added to the model, to accommodate the cur-
vilinear relationship of HRV with age.7 In further analyses, heritabil-
ity estimates of HRV indices were adjusted for a history of diseases 
(cardiovascular disease, hypertension, and type 2 diabetes mellitus) 
and antidepressant use. We did not include smoking and alcohol use 
as additional covariates in our models as we have previously shown 
that the influence of these lifestyle factors on HRV was negligible.7 
Here we also confirmed for BP that addition of these lifestyle factors 
as covariates to the model only had minimal impact on heritability 
estimates (Table S1 in the Data Supplement). We report proportion of 
variance explained by these covariates. The analyses were performed 
using ASReml 4.1 software.25 ASReml is a statistical package that fits 
the linear mixed models using restricted maximum likelihood to esti-
mate the variance components.
We additionally estimated the genetic correlations using bivar-
iate linkage disequilibrium score regression26 on the latest publicly 
available genome-wide association study summary statistics for 
HRV27 and BP.28–30
Results
Characteristics of the participants are provided in Table 1. 
Men had a lower heart rate. Means of RMSSD and SDNN 
were significantly higher in women than in men, and the dif-
ference remained significant after correcting the values for 
mean IBI. In general, all BP measures were significantly 
higher in men, and women had a lower body mass index. 
The prevalence of hypertension and type 2 diabetes mellitus 
was higher in men, but no sex difference was seen for cardi-
ovascular diseases. The proportion of antidepressant use was 
significantly higher in women.
Table 2 shows the proportion of phenotypic variances 
explained by additive genetic factors, shared family environ-
ment, and covariates for different traits. Heart rate showed a 
heritability of 22.7%. The univariate narrow-sense heritability 
estimates for the HRV indices ranged from 13.4% to 17.9%. 
Correcting them for the mean IBI slightly lowered h2 esti-
mates for both RMSSD and SDNN. The h2 estimates for BP 
measures ranged from 24.4% for PP to 30.3% for DBP. SBP 
and MAP showed heritability estimates of 28.0% and 30.1%, 
respectively. In addition to the additive genetic influence, we 
calculated the proportions of variance explained by shared 
family environment and covariates of HRV, heart rate, and BP 
measures. The shared family environment contributed 4.5% 
of the variance for heart rate. The contribution of familial en-
vironmental effects to the variance of HRV was negligible. 
With regard to BP, we found small effects of the shared family 
environment that ranged from 0.9% for PP to 3.2% for MAP. 
The percentage of variance explained by the covariates was 
18.4% for SDNN and 19.8% for RMSSD. These contributions 
even became slightly larger, 20.9%, and 23.7%, respectively, 
when the effect of mean IBI was taken into account. Similarly, 
Figure. An example of a 23-member Lifelines 
pedigree extending over 4 generations. 
Numbers: Lifelines subject identifications; 
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the result showed a substantial contribution of covariates for 
BP that ranged from 19.0% for PP to 28.3% for SBP. The in-
cluded covariates explained only 2.6% of the percentage of 
variance for heart rate.
In Table 3, the bivariate genetic, phenotypic, and environ-
mental correlations between HRV and BP are shown. We found 
a significant genetic correlation of −0.60 between RMSSD 
and heart rate and −0.53 between SDNN and heart rate. These 
correlations were reduced to −0.38 and −0.22, respectively, 
when HRV values were corrected for the effect of mean IBI. 
There were negative genetic correlations between RMSSD and 
BP-related traits with a correlation of −0.20 with SBP, −0.15 
with DBP, −0.18 with MAP, and −0.14 with PP that were con-
sistent significantly different from zero. Similarly, there were 
slightly smaller but significantly consistent correlations be-
tween SDNN and the BP measures. However, the correlation 
between SDNN and PP was not statistically significant. When 
repeating the analyses with HRV measures corrected for the 
mean IBI, phenotypically HRV and BP measures still showed 
negative correlations (ranging from −0.05 to −0.07) with the 
highest correlation observed between corrected RMSSD and 
SBP, but they were smaller than for the uncorrected HRV values. 
Nevertheless, most genetic correlations remained significantly 
different from zero. All genetic correlations were significantly 
different from 1. The bivariate linkage disequilibrium score 
regression largely confirmed direction and magnitude of our 
results based on the Lifelines pedigree data with estimates of rG 
with RMSSD and SDNN ranging from −0.08 to −0.23 for SBP 
and −0.20 to −0.27 for DBP (Table 4).
Discussion
In this study, we showed that genetic factors significantly in-
fluence the variance in HRV and BP. Our results also show 
significant negative genetic correlations between HRV and 
BP measures, which suggests shared genetic factors partly ex-
plain the inverse association between these traits.
In the present study, we found similar heritability estimates 
for RMSSD and SDNN as in the Framingham Heart Study31 and 
in recent reports from the Oman Family Study.10,11 Our results 
were lower than heritability estimates from the Kibbutzim 
family study in Israel, 39% for SDNN and 41% for RMSSD.9 
The possible explanation for relatively higher heritability values 
in the Israel study might be due to an inclusion of more ho-
mogenous samples. Our heritability estimates for SDNN and 
RMSSD remained significant after taking into account the effect 
of mean heart rate on HRV measures. This finding confirms that 
the genetic influence in HRV measures is largely independent of 
the influence of heart rate. Our results also showed substantial 
Table 1. Characteristics of Study Participants and the Distribution of Heart Rate Variability and Blood Pressure Measurements for Men and Women Separately
Variables Total (N=149 067) Men (n=61 625) Women (n=87 442) P Value*
European ancestry, n (%) 143 892 (96.5) 59 535 (96.6) 84 357 (96.5)  
BMI, kg/m2 25.99 (4.36) 26.29 (3.74) 25.79 (4.74) ≤0.001
Type 2 diabetes mellitus, n (%) 4221 (2.8) 2153 (3.5) 2068 (2.4) ≤0.001
Hypertension, n (%) 48 602 (32.6) 22 061 (35.8) 26 541 (30.4) ≤0.001
Cardiovascular disease, n (%) 9358 (6.3) 3964 (6.4) 5394 (6.2) 0.238
Antidepressant use, n (%) 7842 (5.3) 1993 (3.2) 5849 (6.7) ≤0.001
Heart rate, bpm 67.30 (11.0) 65.81 (11.18) 68.35 (10.76) ≤0.001
RMSSD, ms 37.31 (31.60) 34.43 (29.87) 39.34 (32.61) ≤0.001
lnRMSSD, ln(ms) 3.35 (0.73) 3.27 (0.73) 3.42 (0.72) ≤0.001
RMSSDc, % 3.97 (3.08) 3.57 (2.86) 4.24 (3.21) ≤0.001
lnRMSSDc, ln(%) 1.15 (0.66) 1.04 (0.66) 1.23 (0.65) ≤0.001
SDNN, ms 36.14 (26.40) 34.69 (25.91) 37.15 (26.73) ≤0.001
lnSDNN, ln(ms) 3.36 (0.67) 3.32 (0.69) 3.40 (0.66) ≤0.001
SDNNc, % 3.91 (2.70) 3.68 (2.62) 4.07 (2.74) ≤0.001
lnSDNNc, ln(%) 1.16 (0.63) 1.09 (0.65) 1.22 (0.62) ≤0.001
SBP,† mm Hg 126.78 (16.76) 131.66 (15.42) 123.34 (16.82) ≤0.001
DBP,† mm Hg 74.59 (10.25) 77.33 (10.36) 72.65 (9.72) ≤0.001
MAP, mm Hg 91.98 (11.61) 95.44 (11.21) 89.55 (11.27) ≤0.001
PP, mm Hg 52.19 (11.41) 54.32 (10.66) 50.69 (11.68) ≤0.001
Means (SD) are shown unless indicated otherwise. BMI indicates body mass index; BP, blood pressure; DBP, diastolic blood pressure; ln, logarithmic transformation; 
lnRMSSDc, log-transformed corrected root mean square of successive differences; lnSDNN, log-transformed SD of normal-to-normal intervals; lnSDNNc, log-
transformed corrected SD of normal-to-normal intervals; MAP, mean arterial pressure; PP, pulse pressure; RMSSD, root mean square of successive differences; 
RMSSDc, corrected root mean square of successive differences; SBP, systolic blood pressure; SDNN, SD of normal-to-normal intervals; and SDNNc, corrected SD of 
normal-to-normal intervals.
*Age-adjusted P value.
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heritability of BP measured in supine position ranging from 
24.4% for PP to 30.3% for DBP. These findings are slightly 
higher than heritability estimates reported in previous family 
studies,10,16,17 which might be due to the large sample size. A small 
study in Sweden reported that none of the BP measures were 
heritable,32 and another small study conducted in the Seychelles 
reported a nonsignificant heritability for DBP but a higher one 
than we found for PP (h2=24.4%).18 However, both of these 
studies were likely underpowered (n=260 and 314 participants, 
respectively). Only one family study from Nigeria33 reported a 
heritability estimate for MAP and found a slightly higher herit-
ability compared with our study (36% versus 30%). Differences 
in heritability estimates could be varying between populations 
due to different ethnic backgrounds of study participants.
The present study shows consistently significant (from zero) 
and negative genetic correlations between HRV and BP, partic-
ularly with SBP and DBP. This is in line with previous findings 
from cross-sectional4,34 and prospective studies5,6 that reported 
lower HRV is associated with high BP. This confirms our hypo-
thesis that shared genetic factors might also explain the negative 
associations between HRV and BP. In agreement with this, the 
genetic correlations using bivariate linkage disequilibrium score 
regression on genome-wide association study summary statis-
tics for HRV27 and BP28–30 show largely consistent estimates. On 
the contrary, the Oman Family study10 recently reported a non-
significant genetic correlation. However, the authors admittedly 
recognize that the sample size of their study might have been too 
small to detect the underlying genetic contributions.
A major strength of our study is that it constitutes the 
largest family study to date on the subject, providing ample 
power for precise estimates of heritability and genetic overlap. 
Unlike previous studies,9–11 we applied a recommended cor-
rection method to adjust the well-known effect of heart rate 
on HRV to recalculate heritability estimates. Furthermore, 
familial effects were included in the analysis to minimize 
overinflation of the heritability estimates due to the common 
environment shared by family members. Our study, however, 
acknowledges the following limitations. First, antihyperten-
sive treatments might obscure familial contributions to BP 
variations.35 However, we adjusted the measured BP values 
by adding 15 mm Hg to measured SBP and 10 mm Hg to 
Table 2. Heritability Estimates and Proportion of Variance Due to Shared 
Family Environment and Covariates of HR, HRV, and BP-Related Measures
Variables h2* SE
Variance Due to 
Shared Family 
Environment PVC
HR, bpm 0.227 0.009 0.045 0.026
lnRMSSD, ln(ms) 0.179 0.009 0.006 0.198
lnRMSSDc, ln(%) 0.162 0.009 0.005 0.237
lnSDNN, ln(ms) 0.156 0.009 0.001 0.184
lnSDNNc, ln(%) 0.134 0.009 ≈0 0.209
SBP,† mm Hg 0.280 0.009 0.029 0.283
DBP,† mm Hg 0.303 0.009 0.025 0.217
MAP, mm Hg 0.301 0.009 0.032 0.269
PP, mm Hg 0.244 0.009 0.009 0.190
All heritability estimates were adjusted for age, age2, sex, and body mass 
index. Heritabilities for HRV were additionally adjusted for cardiovascular 
disease, hypertension, type 2 diabetes mellitus, and antidepressant medication 
use. BP indicates blood pressure; DBP, diastolic blood pressure; HR, heart 
rate; HRV, heart rate variability; ln, logarithmic transformation; lnRMSSD, 
log-transformed root mean square of successive differences; lnRMSSDc, log-
transformed corrected root mean square of successive differences; lnSDNN, 
log-transformed SD of normal-to-normal intervals; lnSDNNc, log-transformed 
corrected SD of normal-to-normal intervals; MAP, mean arterial pressure; PP, 
pulse pressure; PVC, proportion of variance explained by covariates; and SBP, 
systolic blood pressure.
*All heritability estimates were significantly different from zero.
†BP values were corrected for antihypertensive use.















HR −0.56 (0.002) −0.60 (0.02) −0.54 (0.01) −0.36 (0.002) −0.38 (0.03) −0.34 (0.006)
SBP −0.10 (0.003) −0.20 (0.03) −0.08 (0.01) −0.07 (0.003) −0.16 (0.03) −0.06 (0.007)
DBP −0.07 (0.003) −0.15 (0.03) −0.04 (0.01)* −0.05 (0.003) −0.13 (0.03) −0.03 (0.008)*
MAP −0.09 (0.003) −0.18 (0.03) −0.06 (0.01) −0.06 (0.003) −0.16 (0.03) −0.05 (0.008)
PP −0.08 (0.003) −0.14 (0.03) −0.07 (0.01) −0.06 (0.003) −0.10 (0.03) −0.05 (0.007)
 LnSDNN LnSDNNc
HR −0.40 (0.002) −0.53 (0.03) −0.36 (0.01) −0.15 (0.003) −0.22 (0.04) −0.14 (0.007)
SBP −0.08 (0.003) −0.16 (0.03) −0.06 (0.01) −0.04 (0.003) −0.11 (0.03) −0.03 (0.007)*
DBP −0.06 (0.003) −0.13 (0.03) −0.03 (0.01)* −0.03 (0.003) −0.11 (0.03) −0.02 (0.007)*
MAP −0.07 (0.003) −0.16 (0.03) −0.05 (0.01) −0.04 (0.003) −0.11 (0.03) −0.03 (0.007)*
PP −0.06 (0.003) −0.10 (0.03) −0.05 (0.01) −0.03 (0.003) −0.05 (0.04)* −0.02 (0.007)*
Models were adjusted for age, age2, sex, and BMI. BMI indicates body mass index; DBP, diastolic blood pressure; HR, heart rate; lnRMSSD, log-transformed root mean 
square of successive differences; lnRMSSDc, log-transformed corrected root mean square of successive differences; lnSDNN, log-transformed SD of normal-to-normal 
intervals; lnSDNNc, log-transformed corrected SD of normal-to-normal intervals; MAP, mean arterial pressure; PP, pulse pressure; r
E





, phenotypic correlation; and SBP, systolic blood pressure.
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measured DBP level as recommended by Tobin et al.23 This 
correction approximates pretreatment BP values and may re-
store the correct population ranking of BP values to a large 
extent and optimize estimates of the genetic variance compo-
nent. Second, because a vast majority (96.5%) of participants 
are of Caucasian ancestry, the results of this study cannot be 
generalized to other ethnicities. Finally our study was lim-
ited to time-domain parameters SDNN and RMSSD because 
ultrashort ECG recordings are too short to assess frequency-
domain HRV parameters.1
To conclude, in this large family study, we showed that 
the contribution of genetic factors to the variance of HRV 
(ranging from 15.6% to 17.9%) and BP (ranging from 24.4% 
to 30.3%) in the general population are substantial. The sig-
nificant negative genetic correlations between HRV and BP 
indicate that genes (genetic pathways) for HRV and BP par-
tially overlap.
Perspectives
This implies the need for more studies in the future to iden-
tify more genetic variants as the variance explained by known 
common single-nucleotide polymorphisms discovered in pre-
vious genome-wide association studies is still low (0.9%–
2.3% for HRV measures and 2.9%–5.7% for BP measures).27,30 
The negative genetic correlations between HRV and BP are in 
line with a causal effect of cardiac vagal control in the devel-
opment of hypertension. However, some more discussion is 
warranted what the results may mean: (1) pleotropic genes, 
(2) causal effect, or (3) reverse causation, meaning an increase 
in BP causes compensatory changes in cardiac autonomic 
nervous system activity that lead to reduced HRV. Mendelian 
randomization—a statistical approach to test the direction of 
causality in epidemiologic studies—may be considered in fu-
ture studies to overcome this problem. If a causal effect was 
to be confirmed in future studies, this would have potential 
implications for prevention and treatment of hypertension.
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What Is New?
•	This is the largest family study to date (>29 000 families) to estimate 
heritability of heart rate variability (HRV) and blood pressure (BP) and 
determine their genetic overlap.
•	We report significant negative genetic correlations between HRV and BP 
in a family study for the first time.
•	We used 2 independent approaches to estimate the genetic correla-
tions showing largely consistent results (familial relationships in ped-
igree data and linkage disequilibrium score regression models using 
genome-wide association study data).
What Is Relevant?
•	The significant negative genetic correlations between HRV and BP sup-
port previous cross-sectional and prospective epidemiological studies 
that report an association between cardiac autonomic dysregulation and 
hypertension.
Summary
Our study showed that contributions of genetic factors to the vari-
ance of HRV and BP in the general population are substantial. The 
significant negative genetic correlations between HRV and BP indi-
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